[Federal Register Volume 84, Number 188 (Friday, September 27, 2019)]
[Notices]
[Page 51171]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-20992]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Capsid-Free AAV
Vectors, Compositions, and Methods for Vector Production and Gene
Delivery
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Heart, Lung and Blood Institute (NHLBI), National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an exclusive patent license to Generation
Bio Co. (``Generation Bio''), a company based in Cambridge,
Massachusetts (in the exclusive field specified below), and a co-
exclusive license to Generation Bio and Spark Therapeutics, a company
based in Philadelphia, Pennsylvania (in the co-exclusive field
specified below), to practice the inventions embodied in the patent
application listed in the Supplementary Information section of this
notice.
DATES: Only written comments and/or applications for a license which
are received by the NHLBI Office of Technology Transfer and Development
within 15 days from the date of publication of this notice in the
Federal Register will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Uri Reichman, Ph.D., MBA, Senior Licensing and
Patenting Manager, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD
20892-2479, phone number 301-435-4616, or [email protected].
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are included in the
intellectual property to be licensed under the prospective agreements
to Generation Bio and Spark Therapeutics: NIH reference #E-241-2010.
U.S. patent 9,598,703 issued March 03, 2017; Israeli patent 228328
issued December 01, 2018; Australian patent 2012228376 issued October
05, 2017, and pending applications in Brazil (BR 11 2013 023185 8 A2),
Canada (application 2829518), China (application 201280022523.5),
Europe (application 12 708035.6), India (application 8000/DELNP/2013),
Japan (application 2013-557138), and S. Korea (application10-2013-
7026982).
The invention is jointly owned by the Government of the United
States and by the following French institutions: Association Institut
De Myologie, Sorbonne University, INSERM, and CNRS. The patent rights
in these inventions have been assigned to the Government of the United
States of America, and to the French institutions by their respective
employees who are the inventors of the subject matter claimed in the
patent rights. The prospective patent license will be granted worldwide
and in fields of use not broader than the following:
Exclusive field: Electroporation-mediated delivery of DNA-based
vectors to express therapeutic molecules for the treatment or
prevention of human diseases.
Co-exclusive field: The treatment or prevention of cancer by
administration of DNA-based vectors (with the exception of
electroporation mediation) to express therapeutic molecules.
All Fields of Use with the exception of the aforementioned fields
are available for licensing by other parties on nonexclusive terms.
The subject technology provides DNA-based constructs for human
therapeutics or preventative therapies. Such DNA-based constructs may
be useful in gene therapy for treating genetic disorders, or other
diseases by expressing therapeutic molecules. These constructs are AAV
genome-based, where the gene of interest (therapeutic payload) is
inserted between two ITRs (Inverted Terminal Repeats). The resulting
constructs are devoid of the AAV capsid, and thus nonviral. They are
advantageous over conventionally used AAV vectors, as they are non-
immunogenic. They are also advantageous over plasmid-based expression
constructs since they are of eukaryotic origin and thus devoid of the
bacterial-type DNA methylation as typically present in plasmids.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive patent license will be royalty
bearing and may be granted unless within fifteen (15) days from the
date of this published notice, the NHLBI receives written evidence and
argument that establishes that the grant of the license would not be
consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are timely filed in response to this notice will be treated as
objections to the grant of the contemplated exclusive patent license.
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Dated: September 17, 2019.
Uri Reichman Sr.,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2019-20992 Filed 9-26-19; 8:45 am]
BILLING CODE 4140-01-P